Having determined the palmitoylation motif of APLNR, we designed a short substrate sequence to competitively inhibit the palmitoylation of endogenous APLNR. This competitive peptide, which targets the APLNR palmitoylation site together with morphine, can inhibit the development of NCP, which include pain incidence, microglial activation, and inflammatory component launch https://collinptqpz.timeblog.net/62643727/details-fiction-and-block-pain-receptors-with-proleviate